Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital
Phase 4
Completed
- Conditions
- Diabetes
- Interventions
- Drug: Glargine insulin
- Registration Number
- NCT01203774
- Lead Sponsor
- University of Colorado, Denver
- Brief Summary
In this study the investigators would like to test the hypothesis that in diabetic patients discharged from the hospital, SoloSTAR Glargine insulin will be superior to syringe-injected Glargine in terms of diabetes control, compliance, and patient satisfaction and preference. The investigators will test this hypothesis in a randomized, crossover trial.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 43
Inclusion Criteria
- All patients with type 1 and 2 diabetes discharged from the hospital with recommendations to take Glargine
Exclusion Criteria
- Patients unwilling to participate and patients incapable of complying with the study regimen, such as patients with alcohol and drug addiction problems and patients with severe mental illness
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Pen-administered vs syringe-admnistered Glargine Glargine insulin SoloSTAR pen-administered Glargine insulin then syringe-administered Glargine insulin Syringe-administered vs pen-administered Glargine Glargine insulin Syringe-administered Glargine insulin and then pen-administered Glargine insulin
- Primary Outcome Measures
Name Time Method HbA1c at Three Months of Each Period of Treatment Baseline, Month 3 (End of Intervention 1), Month 6 (End of intervention 2) Data was collected by group
- Secondary Outcome Measures
Name Time Method Compliance and Patient Satisfaction 6 months of treatment after discharge from the hospital
Trial Locations
- Locations (1)
University of Colorado Denver
🇺🇸Aurora, Colorado, United States